SCHEMBL13166342

SCHEMBL13166342

CS/C(=N/C(=O)c1nc(Cl)c(N)nc1N)NC(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 9/20 0.49
ALDH1A1 P00352 5/20 0.49
SCNN1A P37088 5/20 0.49
KDM4E B2RXH2 4/20 0.49
HPGD P15428 4/20 0.49
HSD17B10 Q99714 4/20 0.49
CYP1A2 P05177 4/20 0.49
GLA P06280 3/20 0.49
LMNA P02545 3/20 0.49
SLC9A5 Q14940 3/20 0.49
GAA P10253 2/20 0.49
TSHR P16473 2/20 0.49
SLC9A1 P19634 2/20 0.49
FTO Q9C0B1 2/20 0.49
CYP2D6 P10635 2/20 0.49
SLC22A1 O15245 1/20 0.49
HTR1A P08908 1/20 0.49
MAOA P21397 1/20 0.49
ADORA2A P29274 1/20 0.49
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL936758 1.00 PLAU (0.49) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL936760 1.00 PLAU (0.49) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL17806181 0.81 SCNN1A (0.44) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL16344600 0.81 SCNN1A (0.44) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL17919160 0.81 SCNN1A (0.44) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL12942321 0.80 PLAU (0.59) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL15128479 0.80 PLAU (0.59) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL12882916 0.79 PLAU (0.57) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL13166182 0.78 PLAU (0.52) PLAUALDH1A1SCNN1AKDM4EHPGD
SCHEMBL4884823 0.73 PLAU (0.48) PLAUALDH1A1SCNN1AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803804-B2 Substituted pyrazines for use in the treatment of inflammatory or allergic conditions NOVARTIS AG (CH) 2010-09-28 US disclosed
US-7803804-B2 Substituted pyrazines for use in the treatment of inflammatory or allergic conditions NOVARTIS AG (CH) 2010-09-28 US disclosed
US-20080312217-A1 Organic Compounds NOVARTIS AG 2008-12-18 US disclosed
US-20080312217-A1 Organic Compounds NOVARTIS AG 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312217-A1 Organic Compounds TRPA1, TRPV1, CHRM1 PLAU 2908/4885ALDH1A1 567/4885SCNN1A 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.